Argen-X lands AbbVie

April 25, 2016 News BioVox

Argen-X starts a collaboration with the global biopharmaceutical company AbbVie to develop and commercialize its novel immuno-oncology drug candidate, ARGX-115. ARGX-115 is  a preclinical-stage human antibody program targeting GARP, a protein believed to contribute to immunosuppressive effects of T-cells. 

Argen-X will receive an upfront payment of 35,3 million euros and subsequent preclinical milestone payments of 17,7 million dollar, for a total of 50 million euros. AbbVie may exercise an exclusive option to license the ARGX-115 program and assume responsibility for further clinical development and commercialization.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts


* indicates required

Intuit Mailchimp